{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,17]],"date-time":"2024-07-17T01:34:37Z","timestamp":1721180077495},"reference-count":52,"publisher":"Oxford University Press (OUP)","issue":"21","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,11,1]]},"DOI":"10.2146\/ajhp150635","type":"journal-article","created":{"date-parts":[[2016,10,21]],"date-time":"2016-10-21T06:08:08Z","timestamp":1477030088000},"page":"1745-1754","source":"Crossref","is-referenced-by-count":3,"title":["Evolving therapies for the management of chronic and acute decompensated heart failure"],"prefix":"10.1093","volume":"73","author":[{"given":"Jennifer C.","family":"Cook","sequence":"first","affiliation":[{"name":"Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard H.","family":"Tran","sequence":"additional","affiliation":[{"name":"Division of Pharmacotherapy and Experimental Therapeutics, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. Herbert","family":"Patterson","sequence":"additional","affiliation":[{"name":"Division of Pharmacotherapy and Experimental Therapeutics, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jo E.","family":"Rodgers","sequence":"additional","affiliation":[{"name":"Division of Pharmacotherapy and Experimental Therapeutics, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","reference":[{"key":"key\n\t\t\t\t2019041103110620200_b1-0731745","first-page":"e29","article-title":"Heart disease and stroke statistics\u20142015 update: a report from the American Heart Association","volume":"131","author":"Mozaffarian","year":"2015","journal-title":"Circulation"},{"key":"key\n\t\t\t\t2019041103110620200_b2-0731745","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1161\/CIRCULATIONAHA.110.979500","article-title":"Natriuretic peptide testing in heart failure","volume":"123","author":"Kim","year":"2011","journal-title":"Circulation"},{"key":"key\n\t\t\t\t2019041103110620200_b3-0731745","first-page":"e240","article-title":"2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on practice guidelines","volume":"128","author":"Yancy","year":"2013","journal-title":"Circulation"},{"key":"key\n\t\t\t\t2019041103110620200_b4-0731745","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.jchf.2014.09.001","article-title":"Combined neprilysin and renin-angiotensin system inhibition for the treatment of heart failure","volume":"2","author":"Vardeny","year":"2014","journal-title":"JACC Heart Fail"},{"key":"key\n\t\t\t\t2019041103110620200_b5-0731745","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1161\/01.CIR.0000029801.86489.50","article-title":"Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE)","volume":"106","author":"Packer","year":"2002","journal-title":"Circulation"},{"key":"key\n\t\t\t\t2019041103110620200_b6-0731745","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.amjhyper.2003.09.014","article-title":"Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial","volume":"17","author":"Kostis","year":"2004","journal-title":"Am J Hypertens"},{"key":"key\n\t\t\t\t2019041103110620200_b7-0731745","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1177\/0091270009343932","article-title":"Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi)","volume":"50","author":"Gu","year":"2010","journal-title":"J Clin Pharmacol"},{"key":"key\n\t\t\t\t2019041103110620200_b8-0731745","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1517\/14656566.2015.1000300","article-title":"LCZ696: a new paradigm for the treatment of heart failure?","volume":"16","author":"Minguet","year":"2015","journal-title":"Expert Opin Pharmacother"},{"key":"key\n\t\t\t\t2019041103110620200_b9-0731745","unstructured":"ClinicalTrials.gov. A study of LCZ696 in subjects with mild and moderate hepatic impairment compared with normal healthy volunteers. https:\/\/clinicaltrials.gov\/show\/NCT01621633 (accessed 2015 May 25)."},{"key":"key\n\t\t\t\t2019041103110620200_b10-0731745","volume-title":"Entresto (sacubitril and valsartan) prescribing information","year":"2015"},{"key":"key\n\t\t\t\t2019041103110620200_b11-0731745","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041103110620200_b12-0731745","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1016\/S0140-6736(12)61227-6","article-title":"The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial","volume":"380","author":"Solomon","year":"2012","journal-title":"Lancet"},{"key":"key\n\t\t\t\t2019041103110620200_b13-0731745","unstructured":"ClinicalTrials.gov. Efficacy and safety of LCZ696 compared to valsartan, on morbidity and mortality in heart failure patients with preserved ejection fraction (PARAGON-HF). https:\/\/clinicaltrials.gov\/show\/NCT01920711 (accessed 2015 May 20)."},{"key":"key\n\t\t\t\t2019041103110620200_b14-0731745","volume-title":"Lexicomp Online [online database]","author":"Sacubitril\u2013valsartan [monograph]"},{"key":"key\n\t\t\t\t2019041103110620200_b15-0731745","unstructured":"Institute for Clinical and Economic Review. ICER releases final report on CardioMEMS HF System and Entresto for management of congestive heart failure. www.icer-review.org\/chf-final-report-released (accessed 2015 Dec 11)."},{"key":"key\n\t\t\t\t2019041103110620200_b16-0731745","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1038\/nrd3576","article-title":"Exploring HCN channels as novel drug targets","volume":"10","author":"Postea","year":"2011","journal-title":"Nat Rev Drug Discov"},{"key":"key\n\t\t\t\t2019041103110620200_b17-0731745","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1097\/MJT.0b013e3181758855","article-title":"Characterization of the heart rate-lowering action of ivabradine, a selective I(f) current inhibitor","volume":"15","author":"Borer","year":"2008","journal-title":"Am J Ther"},{"key":"key\n\t\t\t\t2019041103110620200_b18-0731745","volume-title":"Corlanor (ivabradine) prescribing information","year":"2015"},{"key":"key\n\t\t\t\t2019041103110620200_b19-0731745","unstructured":"Crediblemeds.org. Nelfinavir and ivabradine added to QTdrugs.org lists (April2014). www.crediblemeds.org\/blog\/nelfinavir-and-ivabradine-added-list-drugs-avoid\/ (accessed 2015 Dec 14)."},{"key":"key\n\t\t\t\t2019041103110620200_b20-0731745","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1007\/s12012-014-9274-y","article-title":"Torsades de pointes induced by the concomitant use of ivabradine and azithromycin: an unexpected dangerous interaction","volume":"15","author":"Cocco","year":"2015","journal-title":"Cardiovasc Toxicol"},{"key":"key\n\t\t\t\t2019041103110620200_b21-0731745","first-page":"426","article-title":"Slow junctional rhythm, QTc prolongation and transient torsades de-pointes following combined use of ivabradine, diltiazem and ranolazine","volume":"62","author":"Mittal","year":"2014","journal-title":"J Assoc Physicians India"},{"key":"key\n\t\t\t\t2019041103110620200_b22-0731745","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/S0140-6736(10)61198-1","article-title":"Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study","volume":"376","author":"Swedberg","year":"2010","journal-title":"Lancet"},{"key":"key\n\t\t\t\t2019041103110620200_b23-0731745","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1016\/j.jacc.2011.12.044","article-title":"Association of heart rate and outcomes in a broad spectrum of patients with chronic heart failure: results from the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity) program","volume":"59","author":"Castagno","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t2019041103110620200_b24-0731745","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.ijcard.2015.02.001","article-title":"Top ten risk factors for morbidity and mortality in patients with chronic systolic heart failure and elevated heart rate: the SHIFT risk model","volume":"184","author":"Ford","year":"2015","journal-title":"Int J Cardiol"},{"key":"key\n\t\t\t\t2019041103110620200_b25-0731745","doi-asserted-by":"crossref","first-page":"e001626","DOI":"10.1161\/JAHA.114.001626","article-title":"Heart rate at hospital discharge in patients with heart failure is associated with mortality and rehospitalization","volume":"4","author":"Laskey","year":"2015","journal-title":"J Am Heart Assoc"},{"key":"key\n\t\t\t\t2019041103110620200_b26-0731745","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1016\/j.jacc.2012.01.020","article-title":"Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose?: findings from the SHIFT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial) study","volume":"59","author":"Swedberg","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t2019041103110620200_b27-0731745","first-page":"684","article-title":"Ivabradine as a heart rate-lowering agent in a patient with end-stage renal failure after heart transplantation","volume":"68","author":"Kurpesa","year":"2010","journal-title":"Kardiol Pol"},{"key":"key\n\t\t\t\t2019041103110620200_b28-0731745","volume-title":"Lexicomp Online [online database]","author":"Ivabradine [monograph]"},{"key":"key\n\t\t\t\t2019041103110620200_b29-0731745","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1111\/j.1751-7133.2008.00030.x","article-title":"The impact of anemia on the prognosis of chronic heart failure: a meta-analysis and systemic review","volume":"15","author":"He","year":"2009","journal-title":"Congest Heart Fail"},{"key":"key\n\t\t\t\t2019041103110620200_b30-0731745","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1093\/eurheartj\/ehq158","article-title":"Iron deficiency: an ominous sign in patients with systolic chronic heart failure","volume":"31","author":"Jankowska","year":"2010","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t2019041103110620200_b31-0731745","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/S0002-9149(03)00740-9","article-title":"Usefulness of anemia as a predictor of death and rehospitalization in patients with decompensated heart failure","volume":"92","author":"Felker","year":"2003","journal-title":"Am J Cardiol"},{"key":"key\n\t\t\t\t2019041103110620200_b32-0731745","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1016\/j.amjcard.2014.09.024","article-title":"Outcomes of patients with anemia and acute decompensated heart failure with preserved versus reduced ejection fraction (from the ARIC study community surveillance)","volume":"114","author":"Caughey","year":"2014","journal-title":"Am J Cardiol"},{"key":"key\n\t\t\t\t2019041103110620200_b33-0731745","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1002\/phar.1412","article-title":"Distinguishing anemia and iron deficiency of heart failure: signal for severity of disease or unmet therapeutic need?","volume":"34","author":"Beavers","year":"2014","journal-title":"Pharmacotherapy"},{"key":"key\n\t\t\t\t2019041103110620200_b34-0731745","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3390\/pharmaceutics3010012","article-title":"The pharmacokinetics and pharmacodynamics of iron preparations","volume":"3","author":"Geisser","year":"2011","journal-title":"Pharmaceutics"},{"key":"key\n\t\t\t\t2019041103110620200_b35-0731745","unstructured":"Injectafer (ferric carboxymaltose) prescribing information. Shirley, NY: American Regent; 2013Jul."},{"issue":"suppl 2","key":"key\n\t\t\t\t2019041103110620200_b36-0731745","first-page":"S93","article-title":"Structure, chemistry, and pharmacokinetics of intravenous iron agents","volume":"15","author":"Danielson","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"key\n\t\t\t\t2019041103110620200_b37-0731745","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.2147\/DDDT.S55499","article-title":"Optimizing iron delivery in the management of anemia: patient considerations and the role of ferric carboxymaltose","volume":"8","author":"Toblli","year":"2014","journal-title":"Drug Des Devel Ther"},{"key":"key\n\t\t\t\t2019041103110620200_b38-0731745","first-page":"362","article-title":"Pharmacokinetics, safety and tolerability of intravenous ferric carboxymaltose: a dose-escalation study in volunteers with mild iron-deficiency anaemia","volume":"60","author":"Geisser","year":"2010","journal-title":"Arzneimittelforschung"},{"key":"key\n\t\t\t\t2019041103110620200_b39-0731745","doi-asserted-by":"crossref","first-page":"169107","DOI":"10.1155\/2013\/169107","article-title":"Direct comparison of the safety and efficacy of ferric carboxymaltose versus iron dextran in patients with iron deficiency anemia","volume":"2013","author":"Hussain","year":"2013","journal-title":"Anemia"},{"key":"key\n\t\t\t\t2019041103110620200_b40-0731745","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1056\/NEJMoa0908355","article-title":"Ferric carboxymaltose in patients with heart failure and iron deficiency","volume":"361","author":"Anker","year":"2009","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041103110620200_b41-0731745","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1093\/eurheartj\/ehu385","article-title":"Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency","volume":"36","author":"Ponikowski","year":"2015","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t2019041103110620200_b42-0731745","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1093\/ndt\/gft251","article-title":"Ferric carboxymaltose in patients with iron-deficiency anemia and impaired renal function: the REPAIR-IDA trial","volume":"29","author":"Onken","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"key\n\t\t\t\t2019041103110620200_b43-0731745","volume-title":"Lexicomp Online [online database]","author":"Ferric carboxymaltose [monograph]"},{"key":"key\n\t\t\t\t2019041103110620200_b44-0731745","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/phar.1548","article-title":"Relaxin: a novel agent for the treatment of acute heart failure","volume":"35","author":"Wilson","year":"2015","journal-title":"Pharmacotherapy"},{"key":"key\n\t\t\t\t2019041103110620200_b45-0731745","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.cardfail.2009.01.008","article-title":"Intravenous recombinant human relaxin in compensated heart failure: a safety, tolerability, and pharmacodynamic trial","volume":"15","author":"Dschietzig","year":"2009","journal-title":"J Card Fail"},{"key":"key\n\t\t\t\t2019041103110620200_b46-0731745","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1016\/S0140-6736(09)60622-X","article-title":"Relaxin for the treatment of patients with acute heart failure (pre-RELAX-AHF): a multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb study","volume":"373","author":"Teerlink","year":"2009","journal-title":"Lancet"},{"key":"key\n\t\t\t\t2019041103110620200_b47-0731745","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(12)61855-8","article-title":"Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial","volume":"381","author":"Teerlink","year":"2013","journal-title":"Lancet"},{"key":"key\n\t\t\t\t2019041103110620200_b48-0731745","unstructured":"Novartis. Media releases\u2014FDA grants breakthrough therapy designation to Novartis\u2019 serelaxin (RLX030) for acute heart failure. www.novartis.com\/newsroom\/media-releases\/en\/2013\/1711047.shtml (accessed 2015 May 24)."},{"key":"key\n\t\t\t\t2019041103110620200_b49-0731745","unstructured":"ClinicalTrials.gov. Efficacy, safety, and tolerability of serelaxin when added to standard therapy in AHF (RELAX-AHF-2). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01870778 (accessed 2015 Dec 15)."},{"key":"key\n\t\t\t\t2019041103110620200_b50-0731745","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.jchf.2013.04.002","article-title":"Prevention of atrial fibrillation by bucindolol is dependent on the beta\u2081389 Arg\/Gly adrenergic receptor polymorphism","volume":"1","author":"Aleong","year":"2013","journal-title":"JACC Heart Fail"},{"key":"key\n\t\t\t\t2019041103110620200_b51-0731745","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1080\/13543784.2016.1181749","article-title":"Potential new drug treatments for congestive heart failure","volume":"25","author":"Tran","year":"2016","journal-title":"Expert Opin Investig Drugs"},{"key":"key\n\t\t\t\t2019041103110620200_b52-0731745","article-title":"Agents with vasodilator properties in acute heart failure","author":"Singh","year":"2016","journal-title":"Eur Heart J"}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ajhp\/article-pdf\/73\/21\/1745\/28334373\/ajhp1745.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,14]],"date-time":"2019-09-14T18:03:30Z","timestamp":1568484210000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/73\/21\/1745\/5101777"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,1]]},"references-count":52,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2016,11,1]]}},"URL":"https:\/\/doi.org\/10.2146\/ajhp150635","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2016,11,1]]},"published":{"date-parts":[[2016,11,1]]}}}